Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-05 · 46 (5)
DOI: 10.1002/phar.70144 ↗At a glance
Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2026-04-08. Written by Xinyi Huang and 4 co-authors. Institution: Department of Pharmacy, New York Presbyterian Hospital, New York, New York, USA. Major MEDLINE topics: Kidney Transplantation, Heart Transplantation, Immunosuppressive Agents, Immunosuppression Therapy. 18 references.
Abstract (original language)
Background
Simultaneous heart–kidney transplantation (SHKT) has become increasingly common over the past decade, accompanied by evolving recipient characteristics and outcomes introduced by the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. However, contemporary data on immunosuppression practices in SHKT recipients remain limited. To address these knowledge gaps, this study characterizes contemporary immunosuppression practices in SHKT recipients and evaluates their association with post‐transplant outcomes. Methods and Results This UNOS registry analysis included adult SHKT recipients from January 2013 to June 2025. We evaluated induction and maintenance immunosuppression strategies and 1‐year outcomes including treated rejection, graft failure, infection, and mortality. Among 2634 recipients, T‐cell depleting agents remained the most used induction strategy (41.3%), followed by basiliximab (36.8%) and no induction (21.9%). Basiliximab use increased post‐2018, while anti‐thymocyte globulin use declined. mTOR inhibitor use at 1 year was highest among patients receiving T‐cell depleting agents. Despite these shifts, adjusted analyses showed no significant differences in 1‐year rejection, graft failure, or mortality across induction groups.
Conclusion
Contemporary SHKT recipients experience similar 1‐year outcomes across induction strategies. Basiliximab may be sufficient for standard‐risk SHKT recipients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, New York Presbyterian Hospital, New York, New York, USA.
- Arnold & Marie Schwartz College of Pharmacy, Long Island University, New York, USA.
- University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
- Division of Cardiology, Department of Medicine, New York Presbyterian Hospital, Columbia University, New York, New York, USA.
- Thomas J. Long School of Pharmacy, University of the Pacific, Sacramento, California, USA.
ORCID profiles: Xinyi Huang, William L Baker, Paolo C Colombo, Douglas L Jennings
Cite
APA
Huang, X., Baker, W. L., Colombo, P. C., Yuzefpolskaya, M., & Jennings, D. L. (2026). Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(5). https://doi.org/10.1002/phar.70144
Vancouver
Huang X, Baker WL, Colombo PC, Yuzefpolskaya M, Jennings DL. Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(5). doi:10.1002/phar.70144
BibTeX
@article{Huang2026,
author = {Huang, Xinyi and Baker, William L and Colombo, Paolo C and Yuzefpolskaya, Melana and Jennings, Douglas L},
title = {Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
volume = {46},
number = {5},
doi = {10.1002/phar.70144}
}
EUVIMED